Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
NCT04922424Phase 1Withdrawn
- Sponsor
- Yale University
- Start
- Sep 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in hypertension (HTN) and hyperlipidemia comparing atorvastatin with Placebo (2 arms). Primary endpoints: Flow Mediated Vasodilation at 30 minutes, Muscle Sympathetic Nerve Activity at 2 hours and 9 more. Planned start Sep 2022; status: withdrawn.
02
Drugs
atorvastatin
03
Conditions
hypertension (HTN)hyperlipidemia
Beyond the preview
Go deeper on NCT04922424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04922424.